Skip to main content
L

Lbx Pharmacy Chain Joint Stock Company — Investor Relations & Filings

Ticker · 603883 LEI · 300300C4YU1D5XYS0O68 Shanghai Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,769 across all filing types
Latest filing 2026-04-22 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 603883

About Lbx Pharmacy Chain Joint Stock Company

Lbx Pharmacy Chain Joint Stock Company operates as a large-scale retail pharmacy enterprise. The company specializes in the distribution and retail sale of a wide range of pharmaceutical products, including prescription medications, over-the-counter drugs, and traditional Chinese medicines. Its product portfolio also encompasses medical equipment, nutritional supplements, and health-related consumer goods. The company utilizes a standardized management model across its extensive network of retail outlets to ensure service quality and product safety. In addition to physical retail operations, the company integrates digital health solutions and online-to-offline (O2O) services to enhance customer accessibility. Its business strategy focuses on providing comprehensive healthcare services and affordable pharmaceutical products to a broad consumer base.

Recent filings

Filing Released Lang Actions
2026年第一季度报告
Interim / Quarterly Report Classification · 1% confidence The document is titled '老百姓大药房连锁股份有限公司2026年第一季度报告' (Laobaixing Pharmacy Chain Co., Ltd. 2026 First Quarter Report). It contains detailed financial statements (Balance Sheet, Income Statement), management discussion on business operations, and key performance indicators for the first quarter of 2026. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q1 2026
2026-04-22 Chinese
2025年度审计委员会履职报告
Governance Information Classification · 1% confidence The document is a detailed report by the company’s Audit Committee on its 2025 annual performance, covering committee composition, meetings held, deliberated items, oversight of external and internal audits, review of internal controls, and overall governance evaluation. It is not an external auditor’s standalone audit report, nor a general financial report or earnings release, but a governance‐focused committee report detailing internal rules, board committee structure, and governance practices. This aligns with the Governance Information category.
2026-04-22 Chinese
2025年度内部控制评价报告
Governance Information Classification · 1% confidence The document is a standalone 2025 Internal Control Evaluation Report (“内部控制评价报告”) issued by the company’s board and management, detailing internal control objectives, evaluation scope, defect standards, conclusions on control effectiveness, and remediation. This is not an annual financial report or an earnings announcement but rather a governance‐focused report on the company’s internal control systems. It best fits the “Governance Information (CGR)” category, which covers reports detailing internal rules, control practices, and governance processes.
2026-04-22 Chinese
关于2026年第一季度主要经营数据的公告
Earnings Release Classification · 1% confidence The document is titled “关于2026年第一季度主要经营数据的公告” and exclusively discloses key Q1 operating metrics (revenue, net profit, cash flow, EPS, segment breakdown, store counts) in a concise format (~3,270 characters). It does not include full interim financial statements or extensive notes typical of a comprehensive quarterly (IR) report. Instead, it provides headline results and segment highlights, consistent with an earnings release. Therefore, it should be classified as an Earnings Release (ER). Q1 2026
2026-04-22 Chinese
关于计提2025年度资产减值准备的公告
Regulatory Filings Classification · 1% confidence The document is a corporate announcement (公告) regarding the board-approved provision for asset impairment for fiscal year 2025. It is not a full annual or quarterly report, not an earnings release, not related to dividends, governance changes, or capital transactions, nor is it merely a publication notice of another report. As there is no dedicated category for asset impairment announcements, this falls into the general regulatory announcement/fallback category.
2026-04-22 Chinese
关于提请股东会授权董事会制定2026年度中期分红方案的公告
Proxy Solicitation & Information Statement Classification · 1% confidence The document is an official announcement by the board proposing a resolution to the shareholders’ meeting – specifically asking shareholders to authorize the board to formulate the 2026 interim dividend plan. It provides background, legal basis and details of the proposed resolution in order to solicit shareholder approval. This is not the dividend amount notice itself, nor a full report, but rather information prepared for a shareholder vote. It therefore fits the “Proxy Solicitation & Information Statement” category (PSI).
2026-04-22 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.